On September 29, a DEA judge paused the proceeding that will decide whether adult-use cannabis moves to Schedule III. Cannabis stocks fell within hours. If you hold an adult-use license, you still pay 280E tax on close to gross profit, and this pause pushes relief further out. Below is what happened, what stays the same, and what to do while you wait.
What the judge ordered
Chief Administrative Law Judge Derek C. Julius stayed the case while he decides whether to admit a new Government Accountability Office report and allow more briefing. Participants who oppose rescheduling asked for the stay. The GAO report, released September 23, found gaps in how DEA and FDA write down their procedures for evaluating and scheduling drugs. Both agencies agreed to fix them.
The government’s response is due October 13, a filing deadline only. The order sets no restart date and no decision date. The report also found that DEA considered HHS recommendations in all 95 cases where required from 2020 through 2025. All 84 completed scheduling decisions matched those recommendations. The findings cover agency process. They do not say the cannabis review was wrong.
What did not change
In April, Attorney General Todd Blanche moved FDA-approved drug products containing marijuana, and marijuana covered by a state medical license, from Schedule I to Schedule III. The stay does not touch that order. Adult-use cannabis is the part still waiting. Until it moves, it stays on Schedule I, and Section 280E still applies. If your license is adult-use only, you still cannot deduct rent, payroll, or marketing. You pay federal tax on something close to gross profit. Every quarter of delay is another quarter of that tax bill.
How the stocks reacted
The market did not take it well. Trulieve fell about 14% after the pause, which came Tuesday afternoon. Trulieve and the AdvisorShares Pure US Cannabis ETF (MSOS) slid after hours, and the selling carried into Wednesday. MSOS dropped roughly 8% to 9%, depending on whether you count the after-hours move or the Wednesday session. A Yahoo Finance piece on October 1 showed Trulieve down about 13% over the past week, though still up about 25% for the year.
Other big names moved as well. Curaleaf dropped about 4.9% over the following sessions, though it trades mainly on the OTC and CSE, so the figure can differ by venue. Canopy Growth fell about 3.8%, the smallest drop of the group.
Why the reaction was so sharp
U.S. multi-state operators took the hardest hit because Section 280E sits at the center of their earnings and cash flow story. Ending it would send tax savings straight to the bottom line. Analysts who were modeling Schedule III soon now have numbers that look premature. The market had also priced a ruling as a near-term catalyst, even though the GAO findings concern agency process and not the science behind rescheduling. Cannabis stocks have become almost a direct proxy for rescheduling headlines. One analyst at TIKR notes that a recommendation before the November midterms now looks less likely.
What to do while you wait
So what does a pause mean for your books? Plan as if 280E applies for the full year ahead for adult use sales. If you have both medical and adult use sales activity, make sure you can clearly delineate between the two. Do not build a budget, a distribution, or a loan covenant around a rescheduling date. Nobody knows when the judge will rule. Nobody knows whether any relief would reach back to prior years either, so do not count on refunds.
Then tighten what you control. Keep clean support for every dollar you put in cost of goods sold. Track inventory costs by product and by period. Document how you allocate costs between COGS and operating expenses. These steps lower your 280E exposure today, and they stay useful whatever the DEA decides. The pause pushes the timeline out. Honestly, I believe the best move is to run your business on the rules that exist today and clean up your books now.
| Key dates September 23: GAO report released September 29: Judge Julius stays the proceeding October 13: Response deadline on the motion |
About the author
Melissa Diaz, CPA, is the co-owner of High Rock Accounting, a firm that provides outsourced accounting, fractional CFO services, and tax strategy to cannabis and peptide operators. Ready to get your 280E position in order? Contact High Rock at highrock.co/contact.
Sources: mg Magazine, Ganjapreneur, Benzinga, TIKR, GAO-26-108623. This article is general information, not tax or investment advice.